drug pipeline

No company bets everything on a single drug, because most drugs fail. Instead it keeps many projects moving through development at once, each at a different stage. The drug pipeline is the whole portfolio of these candidates — the set of programs an organization is advancing from early discovery, through preclinical work and the clinical phases, toward approval. It is the company's stock of future medicines.

The pipeline is usually pictured as a funnel of stages: discovery, preclinical, phase I, II, and III, then regulatory review. Many programs enter at the wide early end and only a few emerge approved, so a healthy pipeline must be wide at the top to yield even a small number of launches. Because each stage demands more time and money than the last, managers weigh the portfolio constantly — advancing the promising, killing the weak early to save resources, and balancing risk across different targets and disease areas.

A pipeline is also how investors and partners judge a company's future, since today's revenue comes from past successes while tomorrow's depends on what is now in development. The honest reality is that pipelines leak heavily through attrition: the published numbers showing only a small fraction of preclinical candidates ever reaching patients are precisely why companies must run several programs in parallel rather than relying on any one.